1. Home
  2. OEC vs AKBA Comparison

OEC vs AKBA Comparison

Compare OEC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion S.A.

OEC

Orion S.A.

HOLD

Current Price

$6.03

Market Cap

319.6M

Sector

Industrials

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.33

Market Cap

380.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OEC
AKBA
Founded
1862
2007
Country
Luxembourg
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
319.6M
380.4M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
OEC
AKBA
Price
$6.03
$1.33
Analyst Decision
Sell
Strong Buy
Analyst Count
4
6
Target Price
$6.44
$5.75
AVG Volume (30 Days)
731.8K
2.5M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
1.32%
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
$1,806,700,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.35
$1.14
52 Week High
$13.02
$4.08

Technical Indicators

Market Signals
Indicator
OEC
AKBA
Relative Strength Index (RSI) 58.93 45.88
Support Level $5.84 $1.30
Resistance Level $6.58 $1.55
Average True Range (ATR) 0.35 0.07
MACD 0.19 -0.00
Stochastic Oscillator 86.00 6.25

Price Performance

Historical Comparison
OEC
AKBA

About OEC Orion S.A.

Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: